When was Ocular Science founded?

Ocular Science was founded in 2015 and raised its 1st funding round 5 years after it was founded.

Where is Ocular Science located?

Ocular Science is headquartered in Manhattan Beach, United States.

Who is the current CEO of Ocular Science?

Anthony Sampietro of Ocular Science.

How many employees does Ocular Science have?

As of Apr 30, 2026, the latest employee count at Ocular Science is 8.

Is Ocular Science a funded company?

Ocular Science is a funded company, having raised a total of $175K across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 09, 2020.

When was the latest funding round of Ocular Science?

Ocular Science's latest funding was a $***** Conventional Debt round on Jan 16, 2026, with participation from 1 investor. Its primary sector is Ophthalmology. In United States, the Ophthalmology sector has seen $778M in funding in 2026 to date.

Where does Ocular Science rank among its competitors?

Ocular Science ranks 852nd amongst 2630 active competitors, of which 905 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of Ocular Science?

Ocular Science's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Among them, Karyopharm secured the most recent funding round in March, 2026.

Ocular Science - 2026 Company Profile, Team, Funding & Competitors

Company Details

Ocular Science is a biotech developing post-operative drop care products for patients who have had vision correction procedures and glaucoma. Their flagship product line Omni, (launched in 2017) includes three post-operative drop formulas, two injection formulas for the administration during surgery and three formulas for the management of glaucoma. Their latest product Gemini, is an amniotic cytokine extract eye drop for dry eye and wound healing, which according to company claims, is a first of its kind.

Website: ocularscience.com
Social
Email ID: *****@ocularscience.com
Phone Number: +1 **********

Key Metrics

Founded Year

2015

Location

Manhattan Beach, United States

Stage

Seed

Total Funding

$175K in 2 rounds

Latest Funding Round

Conventional Debt, Jan 16, 2026, $*****

Investors

Chicago Atlantic

Ranked

852^nd among 2630 active competitors

Employee Count

8 as on Apr 30, 2026

Similar Companies

Annexon & 280 more

View Ocular Science's full profile

Ocular Science has raised a total funding of $175K over 2 rounds. Its first funding round was on Jan 09, 2020. Its latest funding round was a Conventional Debt round on Jan 16, 2026 for $*****. 1 investor participated in its latest round. Ocular Science has 1 institutional investor.

Here is the list of recent funding rounds of Ocular Science:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 16, 2026	1223587	Conventional Debt	9380139	2217164	3281603	6698477
Jan 09, 2020	2349089	Seed	5112097	2872393	2503145	9673413

Access funding benchmarks and valuations. Sign up today!

View details of Ocular Science's funding rounds and investors

Ocular Science's employee count trend

Ocular Science has 8 employees as of Apr 26. Here is Ocular Science's employee count trend over the years:

Uncover Ocular Science's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ocular Science include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Here is the list of Top 10 competitors of Ocular Science, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
3rd	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
5th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 16 others	71/100
852nd	Ocular Science 2015, Manhattan Beach (United States), Seed	Developer of post-operative drop care solutions	$175K	Chicago Atlantic	41/100